Exact Sciences Corp. , a leading innovator in cancer diagnostics, has announced an expanded collaboration with Humana Inc. to broaden access to colorectal cancer (CRC) screening. Starting August 2025, the Cologuard Plus™ test will be offered as an in-network benefit to eligible Humana Medicare Advantage members across the United States.
Humana, the fourth-largest private health insurer in the country, covers approximately 5.8 million Medicare Advantage members.
“We’re proud to make Cologuard Plus more accessible through our partnership with Humana,” said Jake Orville, Executive Vice President and General Manager of Screening at Exact Sciences. “This collaboration supports our shared goal of removing barriers to care and advancing earlier, more effective detection of colorectal cancer—without requiring patients to leave their homes.”
About Cologuard® and Cologuard Plus™
Cologuard® and the recently launched Cologuard Plus™ are FDA-approved, noninvasive, at-home screening tests for colorectal cancer. Developed in partnership with Mayo Clinic, both tests are designed for adults aged 45 and older who are at average risk for CRC.
Cologuard tests analyze stool samples for specific DNA markers and blood linked to colorectal cancer and precancerous lesions. They require no preparation, dietary restrictions, or time off work, making them a convenient alternative to traditional colonoscopies. Cologuard is included in the colorectal cancer screening guidelines of both the American Cancer Society and the U.S. Preventive Services Task Force.
Launched in March 2025, Cologuard Plus enhances the original test by incorporating novel biomarkers, improved lab processing, and greater sample stability. It also significantly reduces false positives—by over 40%—compared to the original test, lowering the need for unnecessary follow-up colonoscopies.
With more than 20 million screenings conducted since 2014, Exact Sciences continues to drive innovation in early cancer detection and expand patient access to life-saving diagnostics.